Dishman Carbogen Amcis Limited
NSE: DCAL · Pharmaceuticals
Snapshot
Unlock Dishman Carbogen Amcis Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Dishman Carbogen Amcis Limited is a global pharmaceutical services company specialising in contract research and manufacturing (CRAMS) and the production of marketable molecules. The company provides a diverse range of products including active pharmaceutical ingredients, fine chemicals, and specialised reagents for the global healthcare and cosmetic industries.
Business Model
The company operates through a B2B model, providing outsourced research and manufacturing services to global pharmaceutical firms alongside the direct supply of bulk drugs and fine chemicals. Revenue is generated through long-term service contracts and the commercial sale of proprietary chemical and vitamin D-based products.
Growth Outlook
Growth is driven by the increasing global demand for outsourced pharmaceutical research and the expansion of high-potency active pharmaceutical ingredient manufacturing capabilities. The company continues to leverage its expertise in complex chemical synthesis to support the development pipelines of global pharmaceutical partners.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent international quality standards and inspections by global health authorities like the US FDA.
- Client Concentration. Reliance on a limited number of large pharmaceutical partners for contract research revenue creates vulnerability to shifts in client R&D spending.
- Currency Volatility. As a global exporter, the company is exposed to fluctuations in foreign exchange rates which can impact profit margins on international contracts.
- Intellectual Property Risk. The nature of contract research involves handling sensitive client data and proprietary processes, making the company susceptible to potential IP disputes or security breaches.
Start your research today
Unlock AI insights, financials, peers and live data on Dishman Carbogen Amcis Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,901 Cr
TTM · consolidated
NET PROFIT
₹16 Cr
TTM · consolidated
EPS
₹1.03
TTM · consolidated
RETURN ON EQUITY
0.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
2.1%
TTM · consolidated
P/E
169.3x
Q1 FY27 · consolidated
EV/EBITDA
8.8x
Q1 FY27 · consolidated
EBITDA MARGIN
18.4%
TTM · consolidated
NET PROFIT MARGIN
-8.5%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.5%
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Dishman Carbogen Amcis LimitedDCAL | ₹2,734 Cr | 169.30 | 8.84 | 0.2% | 18.4% | 0.3% | 2.1% | -33.8% |
Solara Active Pharma Sciences LimitedSOLARA | ₹3,050 Cr | -1030.89 | 18.59 | 15.5% | 13.9% | -0.1% | 6.7% | -4.1% |
HikalHIKAL | ₹2,741 Cr | -81.13 | 13.91 | -5.4% | 14.1% | -2.7% | 0.1% | -14.4% |
Beta Drugs LtdBETA | ₹2,459 Cr | — | — | — | 20.0% | — | — | +17.7% |
Fredun Pharmaceuticals LimitedFREDUN | ₹2,432 Cr | 20.00 | 27.39 | — | 14.9% | 21.3% | 40.9% | +15.0% |
Indoco RemediesINDOCO | ₹2,423 Cr | 820.34 | 20.29 | 12.1% | 9.0% | 0.3% | 8.4% | -3.9% |
As of Q1 FY27
Financials
Dishman Carbogen Amcis Limited
NSE: DCAL · Pharmaceuticals
Snapshot
Unlock Dishman Carbogen Amcis Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Dishman Carbogen Amcis Limited is a global pharmaceutical services company specialising in contract research and manufacturing (CRAMS) and the production of marketable molecules. The company provides a diverse range of products including active pharmaceutical ingredients, fine chemicals, and specialised reagents for the global healthcare and cosmetic industries.
Business Model
The company operates through a B2B model, providing outsourced research and manufacturing services to global pharmaceutical firms alongside the direct supply of bulk drugs and fine chemicals. Revenue is generated through long-term service contracts and the commercial sale of proprietary chemical and vitamin D-based products.
Growth Outlook
Growth is driven by the increasing global demand for outsourced pharmaceutical research and the expansion of high-potency active pharmaceutical ingredient manufacturing capabilities. The company continues to leverage its expertise in complex chemical synthesis to support the development pipelines of global pharmaceutical partners.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent international quality standards and inspections by global health authorities like the US FDA.
- Client Concentration. Reliance on a limited number of large pharmaceutical partners for contract research revenue creates vulnerability to shifts in client R&D spending.
- Currency Volatility. As a global exporter, the company is exposed to fluctuations in foreign exchange rates which can impact profit margins on international contracts.
- Intellectual Property Risk. The nature of contract research involves handling sensitive client data and proprietary processes, making the company susceptible to potential IP disputes or security breaches.
Start your research today
Unlock AI insights, financials, peers and live data on Dishman Carbogen Amcis Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,901 Cr
TTM · consolidated
NET PROFIT
₹16 Cr
TTM · consolidated
EPS
₹1.03
TTM · consolidated
RETURN ON EQUITY
0.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
2.1%
TTM · consolidated
P/E
169.3x
Q1 FY27 · consolidated
EV/EBITDA
8.8x
Q1 FY27 · consolidated
EBITDA MARGIN
18.4%
TTM · consolidated
NET PROFIT MARGIN
-8.5%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.5%
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27